蒂尔泽帕提德:一种新的心血管保护剂,用于2型糖尿病和肥胖症
Muhammad Bilal Sardar1, Zain Ali Nadeem2, Muhammad Babar3
1Department of Cardiology, Allama Iqbal Medical College, Allama Shabbir Ahmed Usmani Road, Lahore 54700, Pakistan.
Current problems in cardiology
|February 28, 2024
概括
蒂尔泽帕提德是一种双GIP/GLP-1受体激动剂,有效降低2型糖尿病和肥胖患者的血压和体重等心血管风险因素. 这种药物有望改善除了降糖效果之外的心脏健康.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 心血管疾病 (CVD) 是全球领先的健康问题.
- 肥胖和糖尿病是心血管疾病的重要危险因素.
- 蒂尔泽帕提德是一种双重的依赖葡萄糖的胰岛素型多 (GIP) 和类似葡萄糖-1 (GLP1) 受体激动剂.
研究的目的:
- 为了评估蒂尔泽帕提德的心脏保护作用.
- 评估蒂尔泽帕提德对2型糖尿病 (T2DM) 和肥胖患者心血管风险因素的影响.
主要方法:
- 从SURPASS-4试验 (T2DM患者) 和SURMOUNT-1试验 (没有T2DM的肥胖患者) 的数据分析.
- 评估血压,体重,HbA1c和脂质配置文件的变化.
主要成果:
- 在SURPASS-4试验中,提尔泽帕提德显著降低了血压,体重和HbA1c.
- 在SURMOUNT-1试验中,蒂尔泽帕提德在没有T2DM的肥胖患者中降低了心脏代谢风险因素.
- 双受体激素改善了脂质配置,胰岛素分泌,炎症和内皮完整性.
结论:
- 蒂尔泽帕提德在降低T2DM和肥胖患者心血管风险因素方面显示出显著的益处.
- 双重GIP/GLP-1受体激动症为控制心脏代谢风险提供了一种全面的治疗方法.
- 需要进一步的研究来证实长期的心血管结果.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Management and Pharmacotherapy
282
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
282
Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K


